Paper28052849
Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
Alobaid AS and 11 others. Antimicrob Agents Chemother, 2017. Cited by 63 papers, by iCite.
Cite this record
ConductScience Library. Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients. Papers, record 28052849. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28052849
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Population Pharmacokinetics of Piperacillin in Nonobese, Obese, and Morbidly Obese Critically Ill Patients.
- PubMed
Topics22
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Anti-Bacterial Agents | Major topic |
| Bacterial Infections | Major topic |
| Obesity, Morbid | Major topic |
| Penicillanic Acid | Major topic |
| Piperacillin | Major topic |
| Adult | |
| Aged | |
| Biological Availability | |
| Body Mass Index | |
| Creatinine | |
| Critical Illness | |
| Drug Administration Schedule | |
| Drug Dosage Calculations | |
| Female | |
| Humans | |
| Infusions, Intravenous | |
| Linear Models | |
| Male | |
| Microbial Sensitivity Tests | |
| Middle Aged | |
| Monte Carlo Method | |
| Piperacillin, Tazobactam Drug Combination |
Source PubMed
References31
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 23404393 | Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian. | J Pharmacokinet Pharmacodyn | 2013 | https://conductscience.org/library/papers/23404393 | PubMed |
| 2 | 16940077 | Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. | Antimicrob Agents Chemother | 2006 | https://conductscience.org/library/papers/16940077 | PubMed |
| 3 | 25747553 | Prevalence of class-I, class-II and class-III obesity in Australian adults between 1995 and 2011-12. | Obes Res Clin Pract | 2015 | https://conductscience.org/library/papers/25747553 | PubMed |
| 4 | 15335147 | Obesity is a risk factor for peritonitis in the Australian and New Zealand peritoneal dialysis patient populations. | Perit Dial Int | 2004 | https://conductscience.org/library/papers/15335147 | PubMed |
| 5 | 20018492 | First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. | Int J Antimicrob Agents | 2010 | https://conductscience.org/library/papers/20018492 | PubMed |
| 6 | 17785973 | Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion. | Chemotherapy | 2007 | https://conductscience.org/library/papers/17785973 | PubMed |
| 7 | 23864417 | Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients. | Pharmacotherapy | 2014 | https://conductscience.org/library/papers/23864417 | PubMed |
| 8 | 12650399 | Risk factors for surgical site infection in spinal surgery. | J Neurosurg | 2003 | https://conductscience.org/library/papers/12650399 | PubMed |
| 9 | 25038549 | The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. | Adv Drug Deliv Rev | 2014 | https://conductscience.org/library/papers/25038549 | PubMed |
| 10 | 26988339 | Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review. | Int J Antimicrob Agents | 2016 | https://conductscience.org/library/papers/26988339 | PubMed |
| 11 | 15255794 | What is the best size descriptor to use for pharmacokinetic studies in the obese? | Br J Clin Pharmacol | 2004 | https://conductscience.org/library/papers/15255794 | PubMed |
| 12 | 26702922 | What is the effect of obesity on piperacillin and meropenem trough concentrations in critically ill patients? | J Antimicrob Chemother | 2016 | https://conductscience.org/library/papers/26702922 | PubMed |
| 13 | 23228881 | Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients. | Int J Antimicrob Agents | 2013 | https://conductscience.org/library/papers/23228881 | PubMed |
| 14 | 11481298 | Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam. | J Antimicrob Chemother | 2001 | https://conductscience.org/library/papers/11481298 | PubMed |
| 15 | 1244564 | Prediction of creatinine clearance from serum creatinine. | Nephron | 1976 | https://conductscience.org/library/papers/1244564 | PubMed |
| 16 | 23188954 | Continuous versus intermittent administration of piperacillin-tazobactam in intensive care unit patients with ventilator-associated pneumonia. | Indian J Crit Care Med | 2012 | https://conductscience.org/library/papers/23188954 | PubMed |
| 17 | 17547502 | Piperacillin-tazobactam: a beta-lactam/beta-lactamase inhibitor combination. | Expert Rev Anti Infect Ther | 2007 | https://conductscience.org/library/papers/17547502 | PubMed |
| 18 | 15548157 | Postoperative infections and antibiotic prophylaxis for hysterectomy in Sweden: a study by the Swedish National Register for Gynecologic Surgery. | Acta Obstet Gynecol Scand | 2004 | https://conductscience.org/library/papers/15548157 | PubMed |
| 19 | 20065329 | Three decades of beta-lactamase inhibitors. | Clin Microbiol Rev | 2010 | https://conductscience.org/library/papers/20065329 | PubMed |
| 20 | 21333028 | Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. | BMC Anesthesiol | 2011 | https://conductscience.org/library/papers/21333028 | PubMed |
Cited by38
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 63 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42802803 | Model-Informed Ceftazidime-Avibactam Dosing Stratified by Renal Function and Renal Replacement Therapy Status in Critically Ill Patients: A Prospective Population Pharmacokinetic and Monte Carlo Simulation Study. | Drug Des Devel Ther | 2026 | https://conductscience.org/library/papers/42802803 | PubMed |
| 41649772 | β-Lactam Antibiotics in Obese Adults: A Review of Population Pharmacokinetic Analyses. | Clin Pharmacokinet | 2026 | https://conductscience.org/library/papers/41649772 | PubMed |
| 41463740 | Seventeen Years of an Antibiotic Stewardship Programme: Trends in Antibiotic Prescribing and Gram-Negative Bacilli Susceptibility at a Quaternary Healthcare Institution. | Antibiotics (Basel) | 2025 | https://conductscience.org/library/papers/41463740 | PubMed |
| 39912647 | Model-informed dose optimization for prophylactic piperacillin-tazobactam in perioperative pediatric critically ill patients. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/39912647 | PubMed |
| 39699210 | Population pharmacokinetics of piperacillin-tazobactam in the plasma and cerebrospinal fluid of critically ill patients. | Antimicrob Agents Chemother | 2025 | https://conductscience.org/library/papers/39699210 | PubMed |
| 39628093 | Utilizing an Opportunistic Clinical Study and Population-Based Pharmacokinetic Models to Identify Rational Empiric Dosing Regimens for Piperacillin-Tazobactam in Critically Ill Patients. | J Clin Pharmacol | 2025 | https://conductscience.org/library/papers/39628093 | PubMed |
| 39334976 | Risk Factors Associated with Antibiotic Exposure Variability in Critically Ill Patients: A Systematic Review. | Antibiotics (Basel) | 2024 | https://conductscience.org/library/papers/39334976 | PubMed |
| 38902929 | Piperacillin/Tazobactam Susceptibility Test Interpretive Criteria for Enterobacterales: Recommendations From the United States Committee on Antimicrobial Susceptibility Testing. | Clin Infect Dis | 2024 | https://conductscience.org/library/papers/38902929 | PubMed |
| 38560542 | The Effect of Vancomycin and Piperacillin-Tazobactam on Incidence of Acute Kidney Injury in Patients With Obesity. | Hosp Pharm | 2023 | https://conductscience.org/library/papers/38560542 | PubMed |
| 38543252 | Modeling Pharmacokinetics in Individual Patients Using Therapeutic Drug Monitoring and Artificial Population Quasi-Models: A Study with Piperacillin. | Pharmaceutics | 2024 | https://conductscience.org/library/papers/38543252 | PubMed |
| 38436564 | Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing. | Clin Microbiol Rev | 2024 | https://conductscience.org/library/papers/38436564 | PubMed |
| 38180719 | Patients with Obesity Should be Recognised as a Special Patient Population During Drug Development of Antibacterial and Antifungal Agents; A Call to Action. | Clin Pharmacokinet | 2024 | https://conductscience.org/library/papers/38180719 | PubMed |
| 36978398 | Predictive Factors of Piperacillin Exposure and the Impact on Target Attainment after Continuous Infusion Administration to Critically Ill Patients. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/36978398 | PubMed |
| 36978342 | Antimicrobial Pharmacokinetics and Pharmacodynamics in Critical Care: Adjusting the Dose in Extracorporeal Circulation and to Prevent the Genesis of Multiresistant Bacteria. | Antibiotics (Basel) | 2023 | https://conductscience.org/library/papers/36978342 | PubMed |
| 36498473 | Pharmacokinetics, Pharmacodynamics, and Dosing Considerations of Novel β-Lactams and β-Lactam/β-Lactamase Inhibitors in Critically Ill Adult Patients: Focus on Obesity, Augmented Renal Clearance, Renal Replacement Therapies, and Extracorporeal Membrane Oxygenation. | J Clin Med | 2022 | https://conductscience.org/library/papers/36498473 | PubMed |
| 35946096 | Chemotherapy and Anticancer Drugs Adjustment in Obesity: A Narrative Review. | Curr Med Chem | 2023 | https://conductscience.org/library/papers/35946096 | PubMed |
| 35924928 | Pharmacodynamics of Piperacillin-Tazobactam/Amikacin Combination versus Meropenem against Extended-Spectrum β-Lactamase-Producing Escherichia coli in a Hollow Fiber Infection Model. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35924928 | PubMed |
| 35724128 | Pharmacodynamic evaluation of piperacillin/tazobactam versus meropenem against extended-spectrum β-lactamase-producing and non-producing Escherichia coli clinical isolates in a hollow-fibre infection model. | J Antimicrob Chemother | 2022 | https://conductscience.org/library/papers/35724128 | PubMed |
| 35625262 | Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35625262 | PubMed |
| 35453185 | Population Pharmacokinetic Model of Piperacillin in Critically Ill Patients and Describing Interethnic Variation Using External Validation. | Antibiotics (Basel) | 2022 | https://conductscience.org/library/papers/35453185 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28052849
GET https://conductscience.org/api/papers/v1/28052849/references?page=2